Predict your next investment

Acucela company logo
HEALTHCARE | Drug Discovery
acucela.com

See what CB Insights has to offer

Founded Year

2002

Stage

Series B | Alive

Total Raised

$13.4M

Last Raised

$13.4M | 17 yrs ago

About Acucela

Acucela Inc. is a biotech company discovering drug therapies for eye diseases. Neurodegenerative retinal diseases such as macular degeneration, Stargardt's disease, retinitis pigmentosa and glaucoma, affect quality of life for over 50 million people worldwide per the company.

Acucela Headquarter Location

21720 23rd Drive SE Suite 120

Bothell, Washington, 98021,

United States

425-527-3260

Latest Acucela News

Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma A/S to Screen Novel VAP-1 Inhibitor Compounds for Inflammatory Skin Diseases

Apr 16, 2020

April 16, 2020 08:00 AM Eastern Daylight Time SEATTLE--( BUSINESS WIRE )--Kubota Vision Inc. (“Kubota Vision”), formerly known as Acucela Inc., a clinical-stage specialty ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the signing of an Open Innovation Agreement with LEO Pharma A/S (“LEO Pharma”) to screen novel Vascular Adhesion Protein-1 (VAP-1) inhibitor compounds discovered by Kubota Vision. LEO Pharma will evaluate the compounds in disease assays for potential therapeutic use in inflammatory skin diseases, such as psoriasis and atopic dermatitis. During R&D activities to develop novel therapeutics for uveitis, diabetic macular edema, dry eye and post-operative eye inflammation, Kubota Vision discovered several novel VAP-1 inhibitors that are very potent and highly selective. VAP-1 inhibitors, also known as Semicarbazide-Sensitive Amine Oxidase (SSAO) inhibitors, are a promising new class of drugs to treat inflammation-driven diseases. While Kubota Vision has focused on inflammatory eye conditions, VAP-1 inhibitors can potentially be used for multiple inflammatory conditions, including acute respiratory distress syndrome induced by viral infections, such as COVID-19, psoriasis, atopic dermatitis, diabetic kidney disease, osteoarthritis, nonalcoholic steatohepatitis (NASH), certain cancers, and several other diseases. LEO Pharma established its Open Innovation screening program to collaborate with external partners, including biopharmaceutical companies and academic institutions, to identify promising new therapies for inflammatory skin diseases. As part of this collaborative initiative, LEO Pharma provides in-house expertise and unique research tools to screen promising molecules with potential in the dermatology field. Results of the collaborative science program allow LEO Pharma to engage with partners in an open dialogue regarding potential strategic business partnerships. For the full text of the press release, please visit here .

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Acucela

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Acucela is included in 4 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

E

Eye Health

711 items

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

B

Biopharmaceuticals

5,881 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Acucela Patents

Acucela has filed 52 patents.

The 3 most popular patent topics include:

  • Ophthalmology
  • Diseases of the eye and adnexa
  • Disorders of choroid and retina
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/13/2020

3/30/2021

Ophthalmology, Diseases of the eye and adnexa, Vision, Interferometers, Disorders of choroid and retina

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/13/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

3/30/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Ophthalmology, Diseases of the eye and adnexa, Vision, Interferometers, Disorders of choroid and retina

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.